Maureen Rutten-van Mölken is Professor of Economic Evaluation of Innovations for Health at the Erasmus School of Health Policy & Management, Erasmus University Rotterdam. She is also the Scientific Director of the Institute for Medical Technology Assessment (IMTA). She teaches “Health Technology Assessment” and “Pharmaceutical Pricing and Market Access” in the Master-program Health Economics Policy and Law at Erasmus University Rotterdam. Her expertise includes economic evaluation studies, either alongside clinical trials or using probabilistic decision-analytic modeling, and outcomes research. She worked in many disease areas, including respiratory diseases (COPD, asthma), rheumatology, diabetes, cardiovascular disease, and Pompe disease. She has a special interest in the cost-effectiveness and the financing and payment of complex multi-faceted interventions that involve system-level changes like integrated care programs, disease management programs, hospital at home programs, outpatient rehabilitation programs, etc. She also has an interest in the health economics of personalized medicine. She has almost 30 years of experience and has been leading many applied economic evaluations and HTA methods-studies leading to high-level publications. She is the coordinator of SELFIE, a Horizon2020 project on integrated care in multi-morbidity, and contributes to Horizon2020 project HEcoPerMed that develops guidance on health economic modeling, and financing and payment strategies for personalized medicine. She was trained as a health scientist and had additional training in health economics and epidemiology. She obtained an MSc in Health Care Policy and Management at Maastricht University (1988), and a PhD in Health Economics, also at Maastricht University (1994). She joined iMTA as a Senior Researcher in 1996. Previously, she was an Assistant Professor in Health Economics and Medical Technology Assessment at the Department of Health Economics of the University of Maastricht.